A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Five NY research centers form Empire State Cellular Therapy Consortium to accelerate cell therapy access for patients.

The gene-editing therapy OTQ923 normalized brain blood flow in 3 sickle cell disease patients, suggesting it may lower stroke ...

Around 2,500 people are living with sickle cell disease in the Bay State, and they are advocating for a bill that would improve quality of life for all those dealing with the disease.

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

Sickle cell disease is one of the most common genetic blood disorders in the world. It affects millions globally, with the highest burden seen in people of African, Caribbean, Middle Eastern, and ...

Sickle cell disease affects about 100,000 people in the U.S., and 90% of patients are Black, according to NIH.

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.